Sherri Cicero

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

André Goy, Rajni Sinha, Michael E. Williams et al. · Journal of Clinical Oncology · 2013 · 349 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial

André Goy, Sevgi Kalayoğlu Beşışık, Johannes Drach et al. · British Journal of Haematology · 2015 · 41 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

André Goy, Rajni Sinha, Michael E. Williams et al. · Blood · 2012 · 17 citations

Medicine, Hematology, Oncology +14